HR
CBAY

Howe & Rusling’s Cymabay Therapeutics CBAY Stock Holding History

Howe & Rusling’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed -$1K – 1223
2022
Q2 		$1K Buy
+200
New +$478 ﹤0.01% 1028
2019
Q2 		– Sell
-50
Closed -$1K – 891
2019
Q1 		$1K Hold
50
– – ﹤0.01% 786
2018
Q4 		$0 Hold
50
– – ﹤0.01% 916
2018
Q3 		$1K Hold
50
– – ﹤0.01% 829
2018
Q2 		$1K Buy
+50
New +$626 ﹤0.01% 791

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Howe & Rusling's CBAY Position: Q3 2022 in Review

Howe & Rusling sold out of Cymabay Therapeutics (CBAY) in Q3 2022, closing a stake of 200 shares — an estimated $1K sold.

Howe & Rusling first reported a position in CBAY in Q2 2018 and held it in 5 quarters. The position peaked at $1K in Q2 2022. 100 funds tracked by Wall St. Rank hold CBAY as of Q3 2022.

  • Howe & Rusling reported no remaining Cymabay Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 200 Cymabay Therapeutics shares in Q3 2022, an estimated $1K.
  • Howe & Rusling first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 5 quarters.
  • Howe & Rusling's Cymabay Therapeutics position peaked at $1K in Q2 2022.
  • 100 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.